Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Geo - "The main observation that we have made over the last two weeks is that the majority of patients in the COVID wards have not been oxygen dependent. SARS-CoV-2 has been an incidental finding in patients that were admitted to the hospital for another medical, surgical or obstetric reason."
https://www.samrc.ac.za/news/tshwane-district-omicron-variant-patient-profile-early-features
Xviolet posted this article few days ago
Danny, I share the same concerns regarding Omicron, doctors in SA are reporting more cold like symptoms and minimal covid patients presenting as breathless (this is our target cohort). From some reading and watching a few videos on the topic one of the many new mutations is from the common cold which has not appeared in any previous VOC to date, scientists are theorising this is why symptoms are appearing to be more like the common cold.
However it’s still early days and Omicron may present different symptoms in countries where it is winter and have a much older population. I still believe sprinter will produce great data however if Omicron turns out to be considerably milder with not many breathless patients then I’m not entirely sure what that means for us as we are specifically targeting the breathless patients in a hospital setting. Anyone else’s thoughts will be much appreciated.
Atb
thsnks for this XV, I understand this is still very early days but the quote below is slightly concerning for us seeing as we are trialling our treatment solely on breathless patients.
"The main observation that we have made over the last two weeks is that the majority of patients in the COVID wards have not been oxygen dependent. SARS-CoV-2 has been an incidental finding in patients that were admitted to the hospital for another medical, surgical or obstetric reason."
Atansoff, its not a rumour or a secret - ODX has submitted with FDA for EUA for professional use not self use. Its in the RNS, maybe you should stop going off of rumours and gossip around the bike shed.
RNS 2nd July
Twatcher,
ODX are not exclusively selling to DAM
DAM are exclusively buying Visitiect
Big difference.
ProfessorSPD, couldn’t find everyone you named but here are a few notable political figures getting the jab.
Nadhim Zahawi: https://twitter.com/nadhimzahawi/status/1326478646303993864?s=21
Matt Hanc0ck:
https://www.itv.com/news/2021-04-29/didnt-hurt-a-bit-thanks-jvt-matt-han****-gets-astrazeneca-jab-from-professor-jonathan-van-tam
Theresa May:
https://twitter.com/theresa_may/status/1365339579709083656?s=21
Boris Johnson:
https://twitter.com/borisjohnson/status/1372984053624938500?s=21
Sadiq Khan:
https://twitter.com/mayoroflondon/status/1362705179305521152?s=21
Sajid Javid:
https://twitter.com/sajidjavid/status/1372243292767842305?s=21
The Queen:
https://www.bbc.com/news/uk-55602007.amp
https://twitter.com/synairgenplc/status/1451239904185290753?s=21
Can someone clarify what is "Dollar amount: $233,167.52" is in reference to on the below link, UOA receivied this from Synairgen to conduct the trial?
https://healthsciences.arizona.edu/connect/grants/randomised-double-blind-placebo-controlled-phase-iii-trial-determine-efficacy-and
Many thanks
Ghia, most holders attention is on ACTIV-2 due to SPRINTER being delayed again and A2 being the most likely next update.
I agree with you that ACTIV-2 is not the be all and end all for Synairgen but it is a major trial we are part of and if we progress it will be the catalyst for a decent rise in SP. Do you really expect investors to not focus on and discuss a trial which is due an update anytime now?
Prion I think you make a great point with regards to A2 measuring viral loads, with SNG001 being inhaled into the lungs I am confident they will see considerable reduction in viral load and this alone will hopefully be enough for them to progress us into P3.
Do we have the viral load data available on the other treatments that have graduated to P3 so far?
I also think many people forget that A2 is not our only route in to the US, if we do not progress we will still have a route via Sprinter albeit a different patient setting.
@Blessed22 “I am not expecting an RNS”
@BeContrarian “we know news could be a little way off just yet.”
Are you guys referring to SG018 p3? If so I agree, p3 results couple months away.
However don’t forget we are still waiting on an update for ACTIV-2 p2, which IMO is way overdue so we could have a RNS tomorrow. I hope so anyways.
Courtesy of @TheLuggage4 on Twitter.
Not sure how this would apply to SNG as no mention of the interferon being inhaled but very interesting and good reading although vast majority went over my head,
https://twitter.com/frontimmunol/status/1434812753051480075?s=21
"So important are IFN-Is, that it is perhaps not surprising that many viruses have evolved mechanisms to block the triggering of IFN-I production and sometimes to additionally block IFN-I signaling."
gggg21, firstly thanks for your continued great research as always. In regards to what you are talking about I do remember Prof Wilkinson mention on one of. His presentations that there could be potential trial for ICU patients, could it be related to this? Just thinking out loudly